This morning Ypsomed and the JDRF announced a new partnership, per a press release;
“Burgdorf/New York – JDRF, the leading global organization funding type 1 diabetes (T1D) research, has announced a partnership with Ypsomed, a Switzerland-based developer and manufacturer of injection and infusion systems, as part of JDRF’s Open-Protocol Automated Insulin Delivery (AID) Systems Initiative. The objective of the project is the development and regulatory approval of the next-generation mylife™YpsoPump® insulin pump supporting incorporation into an automated insulin delivery (AID) system via open-protocol communication with third-party smartphone-based apps and/or other . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.